---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-135602"
form_type: "8-K"
ticker: "TRVI"
cik: "0001563880"
company_name: "Trevi Therapeutics, Inc."
filed_at: "2024-12-12T23:59:59+00:00"
generated_at: "2026-05-29T04:05:00.471177+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Trevi Therapeutics reports positive SSRE for Phase 2b CORAL trial; sample size unchanged at 160 patients.

## Summary
- SSRE analysis on highest 108mg BID dose after 80 patients completed 6 weeks recommended continuing as planned; no sample size increase or futility.
- Trial enrollment 75% complete; topline results from CORAL Phase 2b still expected in first half of 2025.
- Pre-specified conditional power maintained at 80% or greater based on SSRE outcome.
- Other two pre-specified SSRE outcomes (sample size increase or futility) were ruled out.

## SEC filing metadata
- accession: 0000950170-24-135602
- form_type: 8-K
- ticker: TRVI
- cik: 0001563880
- company_name: Trevi Therapeutics, Inc.
- filed_at: 2024-12-12T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1563880/000095017024135602/0000950170-24-135602-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1563880/000095017024135602/trvi-20241212.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-135602
- JSON: https://secwatch.observer/filing/0000950170-24-135602.json
- Plain text: https://secwatch.observer/filing/0000950170-24-135602.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.